DOCUMENTS

99

 

NOTICES

156

 

 

MOTS CLES

Anti-TNF Graft-versus-host disease Pharmacovigilance Glucocorticoids Acute Myeloid Leukaemia AML Ustekinumab Cardiotoxicity ASDAS Aging Anti-HCV Direct Acting Antivirals DAA Vigibase® Sipuleucel-T Intensive care Placebo COVID-19 Abus d'antibiotiques Autoimmune diseases Alcohol Immunotherapy Biologics Stability Network meta-analysis Ankylosing Apre-milast Bacterial rhinosinusitis Epidemiology Sacroiliitis Atopic dermatitis Axial spondyloarthritis Cohort studies Biologic drug Arrhythmia BTK protein Auto-Diagnostic Cardio-oncology Pharmaco-Épidémiologie Quality of life Spondyloarthritis Biologic therapy Biological therapy Psoriasis Adolescent Accelerometer Bacterial Antimicrobial resistance Antibiotic misuse Biological Therapy Cancer Arthritis Infliximab Auto-immune hepatitis Dermatology Beta-lactam antibiotics Treatment Angiotensin receptor blockers Access to care Anti-Bacterial Agents Psoriatic arthritis ArtThese Antibiotic resistance Antimicrobials Drug survival Pregnancy Management Méta-Analyse Anxiety Cardiomyopathy Systematic review Anxiété Antimicrobiens Spondylitis Etanercept Pharmacoepidemiology Biosimilar Pharmaceuticals Amyloidosis Ankylosing spondylitis Anticancer drugs Primary adrenal insufficiency Albinism Immune checkpoint inhibitors Drug reaction Autoimmunity Alitretinoin Antibiotics Meta-Analysis Addiction Biomédicaments Biologic Angiotensin-converting enzyme inhibitors Prostate cancer Adalimumab Atrial fibrillation Endocrine toxicity Biomarkers Ethics Immune-related adverse events Antimicrobial Stewardship Apremilast Azathioprine Adverse side effects

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS